对于治疗可卡因使用障碍的GLP-1R激动剂埃克森纳提德的可行性:一个案例系列研究
Luba Yammine1, Jessica C Balderas, Michael F Weaver
1From the University of Texas Health Science Center at Houston, Houston, TX.
Journal of addiction medicine
|August 14, 2023
概括
葡萄糖类1受体激动剂 (GLP-1RA) 显示出治疗可卡因使用障碍 (CUD) 的前景. 一个案例系列发现延长释放的exenatide在CUD患者中安全且耐受良好,这表明未来试验的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
- 神经科学是一个神经科学.
背景情况:
- 可卡因使用障碍 (CUD) 是一个重大的公共卫生挑战,随着过量服用死亡人数的增加.
- 目前,没有FDA批准的药物有效治疗CUD.
- 用于糖尿病和体重管理的葡萄糖类1受体激动剂 (GLP-1RA) 显示出降低可卡因使用的临床前承诺.
研究的目的:
- 评估延长释放异胺在治疗CUD中的可行性和安全性.
- 为了评估患者每周注射一次埃森纳提德的坚持和满意度.
- 探索exenatide对可卡因使用和相关临床结果的初步影响.
主要方法:
- 一个涉及3名被诊断患有CUD的患者的病例系列.
- 参与者接受了每周一次的2毫克exenatide的皮下注射,持续6周.
- 治疗是以开放式的方式进行的,并与标准的个人药物咨询一起进行.
主要成果:
- 在整个6周的研究期间,观察到出色的患者出席率和遵从性.
- 患者表示对治疗方案的满意度很高.
- 埃克西纳提德一般耐受性良好,没有严重或意外的不良事件.
- 观察到对可卡因使用的影响和临床结果是不同的,但令人鼓舞.
结论:
- 延长释放的exenatide似乎可行和安全的短期治疗CUD.
- 每周注射一次的配方可能会改善这个人群的坚持.
- 在随机对照试验中进行更长时间的进一步研究是有必要的,以确认疗效.
相关概念视频
01:24Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
01:06Oral Hypoglycemic Agents: Glinides
186
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
186
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
396
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
396
01:15Drug Abuse and Addiction: Pharmacological Phenomena
515
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
515
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
01:23Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211